New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy

Table 1 Patient characteristics during first-line doublet chemotherapy according to treatment period

Clinical characteristics	Training set (2012-2015), n = 937	Validation set (2008-2011), n = 946	P value
Sex, male, n (%)	583 (62.2)	637 (67.3)	0.020
Age
Median, range	56 (19-91)	57 (20-85)	0.785
≥ 65 yr, n (%)	257 (27.4)	259 (27.4)	0.981
ECOG PS, n (%)
0/1	799 (85.6)	817 (86.6)	0.531
2/3	134 (14.4)	126 (13.4)
Prior gastrectomy performed	389 (41.5)	412 (43.6)	0.372
Histology, n (%)
WD/MD	212 (22.6)	256 (27.1)	< 0.001
PD/SRC/undifferentiated	691 (73.7)	590 (62.4)
Unclassified	34 (3.6)	100 (10.6)
Status, n (%)
Recurrent	318 (33.9)	334 (35.3)	0.533
Initial metastatic	619 (66.1)	612 (64.7)
Metastasis No., 2 or more	385 (41.5)	363 (38.9)	0.249
Peritoneal metastasis	518 (55.6)	524 (55.9)	0.902
Liver metastasis	160 (17.2)	226 (24.1)	< 0.001
Lung metastasis	45 (4.9)	43 (4.6)	0.795
PALN metastasis	346 (37.3)	352 (37.5)	0.942
Bone metastasis	93 (10.0)	70 (7.5)	0.051
ALP > 120 IU/L, n (%)	201 (21.5)	197 (21.2)	0.868
Albumin < 3.3 g/dL, n (%)	279 (29.8)	249 (26.8)	0.150
Total bilirubin > 1.2 mg/dL, n (%)	62 (6.6)	77 (8.3)	0.177
NLR ≥ 3, n (%)	381 (40.7)	375 (40.3)	0.881

ECOG PS: Eastern Cooperative Oncology Group performance status; WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated; SRC: Signet ring cell; PALN: Para-aortic lymph node; ALP: Alkaline phosphatase; NLR: Neutrophil-lymphocyte ratio.